Joon Lee is ranked #1376 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Joon Lee (Truist Financial) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Joon Lee's stock ratings?

About 54% of Joon's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Joon Lee

TRU

Joon Lee

Truist Financial

Wall Street Analyst

★★★☆☆

#1376

on 13Foresight · ranked by our own returns

54%

Success Rate

+11.6%

Average Return

19 of 35 calls profitable · +1.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 54% of Joon Lee's ratings turned a profit when each position was held for 1 year — averaging +11.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

117 Buy 16 Hold 0 Sell

Joon's Stock Coverage 33 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
EDIT Editas Medicine	Mar 17, 2026	HOLD	Buy +420.3% avg upside 33 analysts	—	+7.5%
VYGR Voyager Therapeutics	Mar 17, 2026	BUY	Strong Buy +284.7% avg upside 23 analysts	—	-10.7%
SLDB Solid Biosciences	Mar 13, 2026	BUY	Strong Buy +92.3% avg upside 23 analysts	—	-5.3%
PRAX Praxis Precision Medicines	Mar 12, 2026	BUY	Strong Buy +92.1% avg upside 24 analysts	$700.00 147.90% Upside	+14.3%
VRTX Vertex Pharmaceuticals	Mar 11, 2026	BUY	Strong Buy -2.7% avg upside 61 analysts	$525.00 16.24% Upside	-6.8%
ANAB AnaptysBio	Mar 09, 2026	HOLD	Strong Buy +26.1% avg upside 26 analysts	$50.00 13.14% Downside	+44.8%
VKTX Viking Therapeutics	Mar 05, 2026	BUY	Strong Buy +141.1% avg upside 30 analysts	—	+0.5%
BMRN BioMarin Pharmaceutical	Mar 03, 2026	BUY	Strong Buy +72.7% avg upside 52 analysts	—	-6.0%
NTLA Intellia Therapeutics	Mar 02, 2026	BUY	Buy +153.7% avg upside 37 analysts	—	-21.6%
CRSP Crispr Therapeutics AG	Mar 02, 2026	BUY	Buy +39.7% avg upside 41 analysts	—	-14.4%
CORT Corcept Therapeutics	Mar 02, 2026	BUY	Buy -45.6% avg upside 15 analysts	—	+127.3%
WVE Wave Life Sciences	Feb 27, 2026	BUY	Strong Buy +261.8% avg upside 28 analysts	—	-58.3%
PTCT PTC Therapeutics	Feb 27, 2026	BUY	Strong Buy -1.4% avg upside 29 analysts	—	+15.2%
ALKS Alkermes	Feb 26, 2026	BUY	Strong Buy -17.5% avg upside 34 analysts	—	+47.6%
CPRX Catalyst Pharma	Feb 26, 2026	BUY	Strong Buy -17.0% avg upside 15 analysts	—	+26.2%
JAZZ Jazz Pharmaceuticals	Feb 25, 2026	BUY	Strong Buy -1.8% avg upside 35 analysts	—	+16.4%
AXSM Axsome Therapeutics	Feb 24, 2026	BUY	Strong Buy -10.6% avg upside 28 analysts	—	+48.2%
RARE Ultragenyx Pharmaceutical	Feb 13, 2026	BUY	Strong Buy +142.0% avg upside 36 analysts	$76.00 176.91% Upside	+12.6%
RAPP Rapport Therapeutics, Inc.	Nov 10, 2025	BUY	Strong Buy +46.2% avg upside 12 analysts	—	+48.0%
LRMR Larimar Therapeutics	Nov 06, 2025	BUY	Strong Buy +413.5% avg upside 21 analysts	—	-2.0%
TSHA Taysha Gene Therapies	Nov 05, 2025	BUY	Strong Buy +103.3% avg upside 21 analysts	—	+53.6%
ARGX Argenx Se	Aug 01, 2025	BUY	Strong Buy -15.9% avg upside 46 analysts	—	+31.0%
KROS Keros Therapeutics	Dec 04, 2024	BUY	Strong Buy +139.8% avg upside 21 analysts	—	-70.1%
CRMD Cormedix	Nov 14, 2023	BUY	Strong Buy +73.5% avg upside 13 analysts	$18.00 107.64% Upside	+251.4%
ARVN Arvinas Holding Company	Jan 17, 2023	BUY	Buy +265.4% avg upside 27 analysts	$65.00 747.38% Upside	+11.1%
RLMD Relmada Therapeutics	Dec 08, 2022	HOLD	Buy +106.4% avg upside 15 analysts	$4.00 40.58% Downside	+18.0%
CYCN Cyclerion Therapeutics	May 05, 2022	BUY	Buy +196.8% avg upside 2 analysts	$14.00 337.42% Upside	-60.1%
ELOX Eloxx Pharmaceuticals	Aug 08, 2019	BUY	Strong Buy +153.9% avg upside 8 analysts	$10.00 28.53% Downside	-53.0%
QURE uniQure	Jun 19, 2019	BUY	Strong Buy +16.1% avg upside 29 analysts	$76.00 64.22% Upside	-13.8%
ABEO Abeona Therapeutics	Jun 19, 2019	BUY	Strong Buy +196.6% avg upside 17 analysts	$20.00 246.56% Upside	-35.8%
SRPT Sarepta Therapeutics	Aug 08, 2014	BUY	Buy +246.5% avg upside 49 analysts	—	+53.8%
ACAD ACADIA Pharmaceuticals	Aug 07, 2014	BUY	Strong Buy +66.0% avg upside 42 analysts	$33.00 52.66% Upside	·
TLPH Talphera	Jul 28, 2014	BUY	Buy +339.6% avg upside 15 analysts	$14.00 1184.49% Upside	-37.4%

🔒 28 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Joon Lee — Frequently Asked Questions

How accurate are Joon Lee's stock ratings?

Based on the calls 13Foresight could measure, about 54% of Joon's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, or +1.5% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Joon ranked on 13Foresight?

Joon Lee is currently ranked #1376 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Joon cover?

Joon most recently has ratings on EDIT, VYGR, SLDB, PRAX, VRTX, ANAB, VKTX, BMRN, NTLA, CRSP, CORT, WVE and 21 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!